Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation
| العنوان: | Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation |
|---|---|
| المؤلفون: | Eibhlin Conneally, Richard Flavin, Lindsey Clarke, James Nolan, Stephen E. Langabeer, Karl Haslam |
| المصدر: | Case Reports in Hematology Case Reports in Hematology, Vol 2015 (2015) |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Pathology, medicine.medical_specialty, lcsh:RC633-647.5, business.industry, Case Report, lcsh:Diseases of the blood and blood-forming organs, General Medicine, Disease, Disease monitoring, medicine.disease, Peripheral blood, Transplantation, hemic and lymphatic diseases, medicine, Myeloid sarcoma, Stem cell, business, Myelofibrosis, JAK2 V617F |
| الوصف: | Monitoring of theJAK2V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is described of aJAK2V617F-positive primary myelofibrosis patient who underwent allogeneic stem cell transplantation. Prospective residual disease monitoring of the peripheral blood failed to detect an extramedullary manifestation of the disease, a periorbital myeloid sarcoma, arising nearly three years after transplant. This case serves to highlight a pitfall in residual disease monitoring for myeloproliferative neoplasm-associated mutations in the post-allogeneic stem cell transplantation setting. |
| تدمد: | 2090-6560 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bb62879a10c1f12832291fef664f23c https://pubmed.ncbi.nlm.nih.gov/26346984 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....1bb62879a10c1f12832291fef664f23c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20906560 |
|---|